Furthermore, CXCR4-mediated targeting and TRAIL-mediated apoptosis induction in tumor cells suggests that ExoCXCR4+TRAIL may be used as an optional therapeutic tool, potentially providing a novel approach for advancing the treatment of brain metastases of breast cancer with anticancer agents. This evidence concerns the gene TNFSF10 and breast carcinoma.